| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg | |||
| 100mg | |||
| Other Sizes |
| Targets |
Others (not specifically classified into major target families). Cimigenol has been suggested to influence estrogenic pathways. It exhibits potent cytotoxic activity against various cancer cell lines, suggesting it may target pathways involved in cell proliferation and apoptosis.
|
|---|---|
| ln Vitro |
Cimigenol exerts potent cytotoxic activity against human cancer cell lines. It shows activity against SMMC-7721 (hepatocellular carcinoma) with a value of 7.87 uM and A-549 (lung carcinoma) with 12.16 uM. These findings indicate that Cimigenol has significant anti-proliferative effects in vitro against multiple cancer types.
|
| ln Vivo |
No specific in vivo activity data is available for Cimigenol. However, it has been suggested that combination of Cimigenol with an autophagy inhibitor may be a valuable strategy for the chemoprevention or treatment of colon cancer. This indicates potential for in vivo efficacy studies in cancer models.
|
| Enzyme Assay |
Cimigenol is typically evaluated in cell-based cytotoxicity assays. Cancer cells (e.g., SMMC-7721, A-549) are seeded in 96-well plates and treated with varying concentrations of Cimigenol for 48-72 hours. Cell viability is assessed using MTT or SRB assays. The IC50 values are calculated from dose-response curves. Binding to potential molecular targets may be assessed using surface plasmon resonance or other biophysical methods, though specific targets are not well defined.
|
| Cell Assay |
The in vitro cellular activity of Cimigenol is evaluated using cancer cell lines such as SMMC-7721 (human hepatocellular carcinoma) and A-549 (human lung carcinoma). Cells are cultured in appropriate media and treated with the compound at various concentrations for a defined period (typically 48-72 hours). Cytotoxicity is measured using standard colorimetric assays (MTT, SRB, or CCK-8). The concentration required to inhibit cell growth by 50% (IC50) is determined.
|
| Animal Protocol |
No specific in vivo animal experimental protocols are available for Cimigenol. Based on its anti-tumor activity, potential in vivo studies would involve xenograft mouse models where tumor-bearing mice are administered Cimigenol via oral gavage or intraperitoneal injection. Dosing regimens and endpoints (tumor volume, body weight, survival) would be determined based on the specific study objectives.
|
| ADME/Pharmacokinetics |
No specific pharmacokinetic data is available for Cimigenol. As a triterpenoid saponin (molecular weight 488.70, formula C30H48O5), it is expected to have poor oral bioavailability due to high molecular weight and polarity. Standard storage conditions are 4degC, protected from light.
|
| Toxicity/Toxicokinetics |
No specific toxicological data is available for Cimigenol. As a natural product with anti-tumor activity, its toxicity profile has not been extensively characterized in preclinical studies. Standard laboratory safety precautions should be observed when handling this compound.
|
| References | |
| Additional Infomation |
Cimigenol is a triterpenoid compound derived from the hydride of cycloatunane. It has been reported in Cimicifugium spp., Cimicifugium dauricum, and other organisms with relevant data. See also: Black cohosh (partial).
Cimigenol is an active compound isolated from Cimicifuga, with potent anti-tumor activity. It is not approved for clinical use and is intended for research purposes only. The compound is a triterpenoid derived from the hydride of cycloartane. Its mechanism of action may involve modulation of estrogenic pathways and induction of cytotoxicity in cancer cells. |
| Molecular Formula |
C30H48O5
|
|---|---|
| Molecular Weight |
488.6991
|
| Exact Mass |
488.35
|
| CAS # |
3779-59-7
|
| PubChem CID |
16020000
|
| Appearance |
White to off-white solid powder
|
| Density |
1.22g/cm3
|
| Boiling Point |
610.6ºC at 760mmHg
|
| Flash Point |
323.1ºC
|
| Index of Refraction |
1.589
|
| LogP |
4.658
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
1
|
| Heavy Atom Count |
35
|
| Complexity |
962
|
| Defined Atom Stereocenter Count |
13
|
| SMILES |
C[C@@H]1C[C@@H]2[C@H](O[C@]3([C@H]1[C@]4(CC[C@@]56C[C@@]57CC[C@@H](C([C@@H]7CC[C@H]6[C@@]4([C@H]3O)C)(C)C)O)C)O2)C(C)(C)O
|
| InChi Key |
CNBHUROFMYCHGI-IEUUZZHOSA-N
|
| InChi Code |
InChI=1S/C30H48O5/c1-16-14-17-22(25(4,5)33)35-30(34-17)21(16)26(6)12-13-29-15-28(29)11-10-20(31)24(2,3)18(28)8-9-19(29)27(26,7)23(30)32/h16-23,31-33H,8-15H2,1-7H3/t16-,17-,18+,19+,20+,21-,22+,23-,26-,27-,28-,29+,30+/m1/s1
|
| Chemical Name |
(1S,2R,3S,4R,7R,9S,12R,14S,17R,18R,19R,21R,22S)-22-(2-hydroxypropan-2-yl)-3,8,8,17,19-pentamethyl-23,24-dioxaheptacyclo[19.2.1.01,18.03,17.04,14.07,12.012,14]tetracosane-2,9-diol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~204.62 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (5.12 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.0462 mL | 10.2312 mL | 20.4625 mL | |
| 5 mM | 0.4092 mL | 2.0462 mL | 4.0925 mL | |
| 10 mM | 0.2046 mL | 1.0231 mL | 2.0462 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
